首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 140 毫秒
1.
B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and immune escape of bladder cancer, B7-H1 expression in 50 cases of bladder cancer was detected by using immunohistochemical method. Survival curves were con- structed using the Kaplan-Meier method and independent prognostic factors were evaluated using the Cox regression model. Our results showed that the positive rate of B7-H1 immunostaining in normal bladder tissue and bladder cancer was 0 and 72% respectively. The expression of B7-H1 was strongly associated with the pathological grade, clinical stage and recurrence (P〈0.05). The survival rate was significantly lower in patients with B7-H1 positive group than in those with B7-H1 negative group and multi-variable analysis revealed that B7-H1 could be regarded as an independent factor in evaluating the prognosis of bladder cancer. It is concluded that the expression of B7-H1 is strongly associated with neoplastic progression and prognosis of bladder cancer. The manipulation of B7-H1 may become a beneficial target for immunotherapy in human bladder cancer.  相似文献   

2.
3.
The expression of X-linked inhibitor of apoptosis protein (XIAP) gene and its effect on chemotherapeutic sensitivity in bladder carcinoma was explored. By using immunohistochemistry, the expression of XIAP was detected in 47 bladder carcinomas and 5 normal bladder tissues. The XIAP gene was transfected into bladder cancer cell line T24 by liposome and the positive clone was screened by G418. Cellular XIAP mRNA level was detected by RT-PCR. Low-dose mitocycin C was administered to induce the apoptosis of T24 cells. The in vitro growth of bladder carcinoma cells was analyzed by MTT colorimetry, and the apoptosis rate was assayed by TUNEL methods. It was found XIAP was moderately expressed in bladder carcinomas with the the positive rate being 78.73% (37/47), but the positive rate was not correlated with carcinoma stages and grades (P<0.05). XIAP mRNA level in transfected T24 cells was significantly increased by 3.8 times as compared with that in the cells not transfected with XIAP. After treatment with low-dose mitomycin C (0.005 and 0.05 mg/mL), the growth rate in XIAP no-transfected control group was increased by (11.60±0.25)% and (16.51±0.87)% (P<0.05), and the apoptosis rate was decreased by (10.1±0.2)% and (11.9±0.2%) (P<0.05) respectively as compared with XIAP transfected group. It was concluded that XIAP was expressed in most of bladder carcimoma samples. Overexpression of XIAP in T24 could significantly reduce the MMC-induced apoptosis of bladder carcinoma, suggesting its effect on the chemothera- peutic sensitivity of T24 cells.  相似文献   

4.
5.
6.
7.
Flow cytometry (FCM) was used to analyze the DNA content of epithelial cells in 26 cases of bladder cancer and 10 cases of nonneoplastic disease. Bladder tumor cells can be identified by aneuploidy or hyperdiploidy in histogram and/or a heterogeneity index (HI) greater than 2.30. The percentage of positive FCM in patients with bladder cancer was 84.62%. With respect to histological grading, it was 77.78% in grade 1, 90.91% in grade 2 and 100% in grade 3. While in nonneoplastic cases it was 10% Urinary exfoliative cytology was examined in all 26 patients with bladder cancer, with an accuracy of 61.54%. The DNA content of tumor cells increased with the increase of tumor grade and stage. Follow up showed that of 22 bladder cancer patients treated conservatively by transurethral resection or partial cystectomy, 8 recurred. The HI value in recurrent cases was higher than that in nonrecurrent cases. Among these 8 patients, 6 were correctly predicted by FCM. FCM appears to be an objective, sensitive and quantitative method for the diagnosis and monitoring of bladder cancer, and may be useful in estimating the prognosis of superficial bladder cancer.  相似文献   

8.
Background  Perivesical fat invasion is considered as an important prognostic factor for bladder cancer. However, the predictive role of perivesical fat invasion in invasive bladder cancer prognosis has never been reported in Chinese patients. The aim of the study was to assess the predictive value of perivesical fat invasion for prognoses of T2 and T3 bladder cancer in Chinese patients.
Methods  One hundred and fifty-one patients who underwent radical cystectomy for pT2-3N0M0 invasive bladder cancer from 2001 to 2007 were studied. Cancer-specific survival rate (CSS) and recurrence-free survival rate (RFS) were compared between the pT2 and pT3 patient groups. Other clinicopathological parameters were also retrospectively analyzed by univariate and multivariate analyses to identify the independent predictor for the prognoses of this cohort.
Results  Average patient age at surgery was 58 years. Ninety (60.3%) patients had grade I and II disease. During follow-up (median 66 months), 27 patients (17.9%) had tumor recurrence and 18 (11.9%) died of bladder cancer. In the univariate analysis, the CSS and RFS curves between T2 and T3 patients showed no significant difference (P=0.756 and 0.354, respectively). Multivariate Cox regression showed that histological classification and grade were independent predictors for CSS, while grade was the sole independent predictor for RFS.
Conclusions  For this group of Chinese patients, perivesical fat invasion did not demonstrate a statistically significant difference in prognosis between T2 and T3 patients. Nontransitional cell carcinoma (non-TCC) and high-grade patients had short CSS, and patients with high-grade tumor had higher recurrent risk.
  相似文献   

9.
Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor (TUR-BT), recurrence and progresses in the bladder are observed in some patients. There are numerous reports of trials of intravesical instillation of anticancer agents with the objective of lowering this recurrence rate. The aim of this study was to compare the prophylactic efficacy and safety of epirubicin (EPI), pirarubicin (THP) and hydroxycamptothecin (HCPT) in superficial bladder cancer.Methods This study enrolled a total of 189 patients who had been diagnosed with superficial bladder cancer during the period from 2004 through 2007 at Beijing Friendship Hospital. All patients were randomly allocated to one of three treatment groups. Patients in group A received 29 doses of EPI 30 mg/30 ml, patients in group B received 29 doses of THP 30 mg/30 ml, and patients in group C received 29 doses of HCPT 30 mg/30 ml, over a period of 24 months.Results The recurrence-free rate in the 2 anthracycline treatment groups (A and B) were significantly better than that of the HCPT treatment group. In the safety evaluation, the incidences of pollakiuria, pain on urination, dysuria, hematuria,and contracted bladder were not significantly different between groups A and B, but some were significantly higher in groups A and B than that in group C.Conclusion The efficacy of EPI and THP was significantly better than HCPT in the prevention of bladder cancer recurrence.  相似文献   

10.
It has been suggested that progression of bladder transitional cell cancer (BTCC) may be regulated at the molecular level by a typical pattern of expression of genes involved in apoptosis. Re-cently Livin, belonging to the inhibitors of apoptosis (IAP) family, has been found to be expressed in most solid tumors, where its expression is suggested to have clinical significance. In order to explore the significance of Livin expression in the development of BTCC, immunohistochemistry and RT-QPCR were used to detect the expression of Livin mRNA in tumor tissues and adjacent normal tissues of 30 cases of BTCC. The results showed that the positive rate of Livin expression in adjacent normal tissues and tumor tissues was 0 and 60% (18/30) respectively. The -△△CT value of Livin in BTCC tissues was 8.0454 (7.4264-8.6644) times of that in adjacent normal tissues. The expression of Livin mRNA had no correlation with tumor pathological grades and clinical stages. It was sug-gested that there was weak expression of Livin mRNA in adjacent normal tissues, but strong in tumor tissues.  相似文献   

11.
目的 研究影响非肌层浸润性膀胱尿路上皮细胞癌复发相关危险因素.方法 回顾性分析2013年1月至2016年4月在本院治疗的非肌层浸润性膀胱尿路上皮癌患者资料共90例,所有患者均经过外科手术治疗,对患者本人或家属通过电话、书信、走访、门诊、膀胱灌注药物同时随访等方式进行随访,主要随访内容有:是否复发、复发时间、是否按时规律用药、再次住院情况等.随访12个月,随访截止时间为2017年4月.根据资料查找,选定相关危险因素的变量,通过单因素分析与Cox回归分析非肌层浸润性膀胱尿路上皮癌的复发相关危险因素与临床意义.结果 90例患者中共36例患者出现术后复发情况,总复发率为40.0%,平均无复发生存时间为19.73个月;单因素中患者年龄、肿瘤数目、肿瘤分期、分级、术后灌注方式与以往复发情况,COX回归多因素分析中显示肿瘤数目、肿瘤分期、肿瘤分级、术后灌注方式、以往复发情况是患者肿瘤复发相关危险因素;而患者性别、肿瘤直径、存在部位、灌注药物种类对肿瘤复发影响效果均不明显(P>0.05).结论 肿瘤数目、肿瘤分期、分级、术后灌注方式与以往复发情况是非肌层浸润性膀胱尿路上皮细胞癌复发的独立危险因素.  相似文献   

12.
目的 检测膀胱癌组织中端粒酶及mdm2基因表达并探讨其临床意义。方法 用免疫组织化学技术 (SP法 )检测 38例膀胱组织标本中端粒酶及mdm2基因蛋白表达。结果 端粒酶在G1和Tis- 1肿瘤中阳性表达率分别低于在G2 G3和T2 - 4中的阳性表达率 ,初发组阳性表达率低于复发组 (P <0 .0 5)。mdm2基因蛋白在Tis- 1肿瘤中阳性表达率显著高于T2 - 4中阳性表达率 (P<0 .0 5) ,初发组中阳性表达率高于复发组中阳性表达率 (P <0 .0 5)。随着病理分级及临床分期的增高 ,端粒酶阳性表达率逐渐增高 ,而mdm2基因蛋白阳性表达率逐渐下降。端粒酶阳性表达与患者术后生存率无关 ,mdm2阴性表达的病例生存率较低。结论 端粒酶染色阳性与mdm2基因蛋白的异常表达与肿瘤的发生及发展有关 ,两者表达均可作为判定膀胱肿瘤恶性程度的重要指标 ,且mdm2阳性表达可提供膀胱癌患者预后信息  相似文献   

13.
目的:探讨HMGA2和E-cadherin在膀胱移行细胞癌组织中的表达及其与临床分期、病理分级及预后的关系。方法:选取健康人正常膀胱组织5例、膀胱移行细胞癌组织49例。49例膀胱移行细胞癌组织分为非肌层浸润组(41例)、肌层浸润组(8例);低级别组(24例)、高级别组(25例)。应用免疫组织化学方法检测正常膀胱组织和膀胱移行细胞癌组织中HMGA2和E-cadherin蛋白的表达情况,并结合临床资料进行分析。结果:5例正常膀胱组织中HMGA2呈阴性表达、E-cadherin呈阳性表达;在49例膀胱癌组织中HMGA2阳性表达率为41%、E-cadherin的阴性表达率为43%;其中在非肌层浸润组(Tis~T1)、肌层浸润组(T2)膀胱癌组织中HMGA2的阳性表达率分别为34%和75%,HMGA2在肌层浸润组阳性表达率显著高于非肌层浸润组 (P<0.05);E-cadherin阴性表达率分别为37%和75%,E-cadherin在肌层浸润组阴性表达率显著高于非肌层浸润组 (P<0.05);在低级别、高级别肿瘤中HMGA2的阳性表达率分别为25%和56%,HMGA2在高级别组阳性表达率显著高于低级别组 (P<0.05),E-cadherin阴性表达率分别为25%和60%,E-cadherin在高级别组阴性表达率显著高于低级别组 (P<0.05);术后随访18~40个月,随访42例膀胱癌患者中复发18例。在复发组与未复发组中HMGA2的阳性表达率分别为56%和25%,HMGA2在复发组阳性表达率显著高于非复发组 (P<0.05);E-cadherin阴性表达率分别为67%和33%,E-cadherin在复发组阴性表达率显著高于非复发组 (P<0.05)。结论:HMGA2、E-cadherin的异常表达与膀胱移行细胞癌的恶性程度有关联,可以作为检测膀胱移行细胞癌临床分期、病理分级及预后的重要指标。  相似文献   

14.
目的:探讨非肌层浸润性膀胱尿路上皮肿瘤组织中PTEN和P53的表达及其临床意义?方法:采用免疫组化SP法,检测121例术前未经化疗患者膀胱癌组织中PTEN和P53的表达情况?进行临床资料随访,分析两者表达与肿瘤的分期?分级以及复发之间的关系?结果:121例标本中PTEN阳性表达89.2%,P53阳性表达39.6%?相关分析证明P53在T1期?高级别肿瘤中的表达明显,与肿瘤分期?分级呈正相关(P < 0.05),PTEN在T1期?高级别肿瘤中的表达较少,与肿瘤分期?分级呈负相关(P < 0.05)?生存分析显示膀胱癌的复发时间间隔与P53的表达有明显相关性,而与PTEN的表达无明显相关性?结论:PTEN?P53的阳性表达可能为明确膀胱肿瘤的生物学行为以及判断肿瘤术后复发提供依据?  相似文献   

15.
目的 讨论二次等离子电切术在非肌层浸润性膀胱肿瘤中的应用价值。 方法 回顾性分析2017年7月—2019年1月于蚌埠医学院第一附属医院泌尿外科行膀胱肿瘤等离子电切术的非肌层浸润性膀胱肿瘤患者113例。其中43例于首次等离子电切术后4~6周行二次电切术的患者为观察组,其余行单次等离子电切术患者70例为对照组。记录并分析以下临床资料,包括一般资料:性别、年龄、BMI、肿瘤大小、数目、术前分期、病理分级;手术相关情况:术后留置导尿时间、术中及术后相关并发症等;术后病理及预后资料:二次等离子电切病理阳性率、2组患者术后肌层浸润率及随访12个月后局部复发率等。 结果 2组患者一般资料和手术相关情况差异无统计学意义(均P>0.05);观察组3例患者(6.98%)二次等离子电切术后病理可见尿路上皮肿瘤细胞;观察组一次等离子电切术后与对照组术后病理明确肌层浸润率(6.98%vs. 7.14%)比较,差异无统计学意义(P>0.05);而二次等离子电切术后肌层浸润率明显高于对照组(20.93%vs. 7.14%),差异有统计学意义(P<0.05);观察组复发率明显低于对照组(2.94%vs. 18.46%),差异有统计学意义(P<0.05)。 结论 二次等离子电切术可以最大限度清除肿瘤组织,提供精准的病理分期,降低复发率,且术中及术后并发症无明显增加。非肌层浸润性膀胱肿瘤行二次等离子电切术可以使患者获益,值得临床推广。   相似文献   

16.
膀胱癌中p53突变及Bcl-2、PCNA表达与细胞的增殖和凋亡   总被引:5,自引:0,他引:5  
目的 探讨膀胱癌中p5 3突变和Bcl 2、增殖细胞核抗原 (PCNA)表达与细胞增殖、凋亡和临床病理学参数之间的关系。方法 SABC免疫组化检测 6 2例膀胱癌标本Bcl 2、p5 3和PCNA的表达。计算肿瘤细胞中PCNA阳性细胞百分比即增殖指数 (PI)。TUNEL法检测细胞凋亡 ,计算肿瘤细胞中凋亡细胞的百分比即凋亡指数 (AI)。结果  6 2例膀胱癌中 ,5 0例 (80 6 % )发生 p5 3突变 ,其中G3 级的突变率为 91 3% ,较G1级 (72 7% )和G2 级(78 5 % )更多见 ,但差异无显著性意义 (P >0 0 5 ) ;T2 期 p5 3突变率 (95 7% )较Ta 1期 (71 8% )高 (P <0 0 1)。14例 (2 2 5 % )发现有Bcl 2表达 ,Bcl 2表达阳性率在G3 级中明显高于G1和G2 级 (P <0 0 5 ) ,但与分期无相关性(P >0 0 5 )。Bcl 2表达与p5 3突变无关。PI为 17 3%~ 4 1 8% (平均为 2 2 4 % ) ,AI为 1 9%~ 3 5 % (平均为2 9% ) ,PI与肿瘤分级、分期相关 ,AI与肿瘤的分级明显相关。结论 p5 3突变与浸润性行为呈正相关。在膀胱癌中 p5 3和PCNA过表达可提示预后。随着肿瘤的进展 ,肿瘤细胞过度增殖可能伴有频繁的凋亡 ,但增殖指数的增加明显强于凋亡指数的增加。  相似文献   

17.
目的:探讨X连锁的凋亡抑制蛋白(XIAP)在膀胱移行细胞癌(BTCC)的表达情况,以及XIAP与BTCC病理分级、临床分期的关系。方法:收集临床上经病理确诊的BTCC手术标本62例,应用免疫组织化学测定肿瘤组织中XIAP的表达情况,将结果进行相关分析。结果:XIAP在膀胱肿瘤中的阳性表达率为67.7%,在正常膀胱移行上皮阳性表达率为23.1%,两者差异有统计学意义(P〈0.005);在Ⅰ、Ⅱ、Ⅲ级BTCC的阳性表达率分别是75.0%、57.9%和66.7%,在浅表性和浸润性BTCC的阳性表达率分别为63.9%和73.1%,阳性表达率各组之间无统计学意义(P〉0.05)。结论:XIAP可能在BTCC的发生、发展中发挥重要作用。  相似文献   

18.
Zhou JT  Cai ZM  Li NC  Na YQ 《中华医学杂志》2006,86(28):1970-1974
目的观察缺氧诱导因子1α(HIF-1α)及其靶基因Glut-1蛋白在膀胱移行细胞癌和肾透明细胞癌中的表达及其临床意义。方法TransAMTM酶联法测定25例膀胱移行细胞癌,16例肾透明细胞癌组织及同一患者远离肿瘤5 cm的癌周正常对照组织中HIF-1α蛋白活性定量;用免疫组织化学方法,对58例膀胱移行细胞癌和38例肾透明细胞癌石蜡组织标本中Glut-1蛋白的表达进行检测。结果HIF-1含量在肾透明细胞癌组织中为(3.38±1.71)μg/孔板,明显高于癌旁正常肾组织(2.23±1.07)μg/孔板,差异有统计学意义(P=0.03)。HIF-1α在膀胱TCC与对照中含量低,差别小,膀胱癌组织HIF-1含量较癌旁正常膀胱组织相比,有增高趋势,但差异无统计学意义(P=0.60)。12例正常膀胱黏膜和16例正常肾组织中无Glut-1蛋白的表达,Glut-1蛋白在膀胱癌和肾癌组织表达均显著增强,Glut-1蛋白在膀胱移行细胞癌中广泛表达,阳性率为77.9%(45/58)。G1、G2、G3膀胱癌组织Glut-1阳性表达率分别为66.7%,89.1%和53.3%。Glut-1蛋白与膀胱肿瘤分级有差异(P=0.029);31例表浅性膀胱癌Glut-1阳性表达率为83.9%,浸润性膀胱癌Glut-1阳性表达率70.4%,两组比较差异无统计学意义(P=0.90),提示Glut-1蛋白的表达与肿瘤分期无关。本组58例均有2年以上的随访,其中31例表浅性膀胱癌2年内有19例复发,12例无复发,复发组19例与未复发组12例Glut-1蛋白的表达分布无差异(P=0.90),提示Glut-1蛋白的表达与表浅性膀胱癌复发无关。在肾透明细胞癌组织中存在Glut-1广泛表达86.9%(33/38)。但Glut-1蛋白的表达与肾癌分级,分期无关。结论HIF-1α的表达可能对肾癌发生,发展起着重要作用,但在膀胱癌中作用还需进一步研究;Glut-1基因参与了肾透明癌和膀胱移行细胞癌的形成过程。  相似文献   

19.
结直肠癌组织中XIAP的表达及其意义   总被引:1,自引:0,他引:1  
目的 探讨结直肠癌组织中凋亡抑制蛋白XIAP的表达及其与各临床病理因素的关系.方法 应用免疫组织化学染色法以及RT-PCR检测87例结直肠癌组织中XIAP的表达情况.结果 结直肠癌、癌旁组织、正常组织中XIAP mRNA表达阳性率分别为64.4%(56/87)、49.4%(43/87)和11.4%(10/87),结直肠癌组织中XIAP mRNA表达阳性率与癌旁组织和正常组织比较均有显著性差异.免疫组化染色显示,87例结直肠癌组织有61例(70.1%)XLAP呈阳性,XIAP表达在不同病理分级之间差异有显著性(P=0.014),在不同的临床分期、肿瘤部位、淋巴结转移之间的差异无显著性.结论 XIAP在结直肠癌中的高表达与结直肠癌的发生可能有关,其是一种具有潜在价值的结直肠癌肿瘤标志物.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号